PharmacoEconomics

Meningococcal Vaccination: Cui Bono?
pp. 315-316(2)
Author: Adis International Limited,

Future Challenges for the Economic Evaluation of Healthcare: Patient Preferences, Risk Attitudes and Beyond
pp. 317-321(5)
Author: Bridges, John F.P.

Pharmacoeconomic Analyses Using Discrete Event Simulation
pp. 323-332(10)
Author: Caro, J. Jaime

Review of the Cost Effectiveness of Immunisation Strategies for the Control of Epidemic Meningococcal Meningitis
pp. 333-343(11)
Authors: Miller, Mark A.; Shahab, Cathryn K.

Health-Related QOL in Acute Exacerbations of Chronic Bronchitis and Chronic Obstructive Pulmonary Disease: A Review of the Literature
pp. 345-363(19)
Authors: Doll, Helen; Miravitlles, Marc

Cost Effectiveness of Budesonide/Formoterol in a Single Inhaler for COPD Compared with Each Monocomponent Used Alone
pp. 365-375(11)
Authors: Löfdahl, Claes-Göran; Ericsson, Åsa; Svensson, Klas; Andreasson, Emma

Modelling Cost Effectiveness and Cost Utility of Sequential DMARD Therapy Including Leflunomide in Rheumatoid Arthritis in Germany: I. Selected DMARDs and Patient-Related Costs
pp. 377-393(17)
Authors: Schädlich, Peter K.; Zeidler, Henning; Zink, Angela; Gromnica-Ihle, Erika; Schneider, Matthias; Straub, Christoph; Brecht, Josef G.; Huppertz, Eduard

Modelling Cost Effectiveness and Cost Utility of Sequential DMARD Therapy Including Leflunomide for Rheumatoid Arthritis in Germany: II. The Contribution of Leflunomide to Efficiency
pp. 395-420(26)
Authors: Schädlich, Peter K.; Zeidler, Henning; Zink, Angela; Gromnica-Ihle, Erika; Schneider, Matthias; Straub, Christoph; Brecht, Josef G.; Huppertz, Eduard